#USA #Las Vegas #Vascular Treatment #REVA Medical #MOTIV

REVA Medical Showcases Groundbreaking Procedures at VIVA26

On October 7, 2026, REVA Medical, LLC, a pioneering medical device company, announced the successful conclusion of a live procedure utilizing their MOTIV® sirolimus-eluting bioresorbable scaffold during the Vascular InterVentional Advances (VIVA) 2026 event held in Las Vegas, Nevada. This event attracted numerous participants, eager to witness advancements in vascular intervention technology.

Live Procedure Highlights

Conducted by Prof. Dr. Andrej Schmidt from the University Hospital Leipzig, the live demonstration featured a 72-year-old female patient suffering from chronic limb-threatening ischemia (CLTI) due to peripheral artery disease (PAD). Classified under Rutherford category 5, she presented with a non-healing ulcer, a critical condition requiring immediate and effective intervention.

During the procedure, Prof. Schmidt successfully employed two MOTIV® scaffolds of dimensions 4.0 mm × 48 mm and 3.5 mm × 24 mm, resulting in successful revascularization of the peripheral artery below the knee. The angiographic results displayed an excellent recovery outcome, underscoring the efficacy of the MOTIV® technology in treating complex vascular diseases.

Latest Clinical Results Presentation

In a separate session focused on late-breaking clinical trials, Dr. Ehrin Armstrong from HCA HealthOne Swedish Medical Center in Denver unveiled a subgroup analysis of the pivotal MOTIV clinical study. This study evaluated clinical outcomes in patients categorized as Rutherford 4 and 5, presenting significant findings regarding the effectiveness of the MOTIV® scaffold compared to standard balloon angioplasty (PTA).

The study included 292 patients with CLTI, aiming to assess the efficacy of MOTIV® against PTA in preserving limb function and ensuring primary patency. Impressively, 69% of participants fell into the more complex Rutherford category 5. The results indicated that after 6 months, 87.2% of patients treated with the MOTIV® scaffold in category 4 maintained limb viability, compared to only 76.3% in the PTA group. In category 5, 77.0% achieved the same outcome versus 55.8% with PTA.

After 12 months, the trends continued, showing 76.7% of Rutherford 4 patients maintaining limb viability (PTA: 54.5%) and 65.7% of Rutherford 5 patients (PTA: 46.2%). Additionally, MOTIV® demonstrated higher acute technical and procedural success rates in both groups, especially in the more challenging category 5 cohort.

Potential and Future Directions

Jeffrey Anderson, President and CEO of REVA Medical, remarked on the day’s events: “The successful procedure and the consistent clinical outcomes observed in Rutherford categories 4 and 5 clearly showcase the potential of our bioresorbable scaffold technology at VIVA26.” His comments reflect the commitment of REVA Medical to meet the needs of patients facing complex vascular diseases below the knee.

Chronic limb-threatening ischemia represents the most severe form of PAD, often leading to debilitating pain, non-healing wounds, and amputations. The MOTIV® scaffold uniquely addresses this issue by opening blocked arteries, providing necessary support during the healing phase, and ultimately being absorbed by the body, leaving no permanent implant behind.

Conclusion

The MOTIV® scaffold’s promising results and the successful live demonstration collectively underscore REVA Medical's role in advancing vascular treatments. As the company promotes its innovative technologies for vascular applications, the medical community anticipates further developments that could reshape care approaches for patients suffering from peripheral arterial diseases. For more on REVA Medical and its mission, visit their LinkedIn page.